地锦草在早期症状性痔中的疗效-一项初步研究。

The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids--a pilot study.

机构信息

Gupta Nursing Home, Laxminagar, Nagpur, India.

出版信息

Eur Rev Med Pharmacol Sci. 2011 Feb;15(2):199-203.

Abstract

BACKGROUND

The medical treatment for hemorrhoids has undergone significant changes on introduction of new pharmaceutical agents in the last decade. Euphorbia Prostrata is a new molecule used for grade I and II hemorrhoids. Beneficial effects of the Euphorbia prostrata in hemorrhoids have multiple mechanisms that are due to its active constituents flavonoids, tannins and phenolic acid. This pilot study was performed to assess the effectiveness of this molecule in early grades of symptomatic hemorrhoids.

MATERIALS AND METHODS

In the present retrospective study, the effect of Euphorbia prostrata on patients with hemorrhoids was observed over a follow up period of 12 weeks. In all, 120 patients were studied. This included 63 males and 57 females. Patients with grade 1 and 2 were prescribed with one tablet of Euphorbia prostrata (Tab Sitcom, Panacea Biotec, India) to be consumed on empty stomach every morning for two weeks. Follow-up was carried out at 2, 4 and 12 weeks after commencement of treatment. The primary end point of the study was control of bleeding and secondary end points were regression of hemorrhoid mass, pruritus and discomfort in the anus.

RESULTS

Ninty-nine patients (82%) had complete cessation of bleeding at the end of two weeks. Six patients needed another 2 week's treatment to achieve complete relief, amounting to a success rate of 87%. Anal itch was relieved in 73% of patients, while anal discomfort subsided in 90% of patients. None of the patient had reported any adversity with consumption of the drug. At the follow-up after 3 months of treatment, no patient reported with symptomatic recurrence. However, 37 of the 79 patients (46%) still had residual hemorrhoids on anoscopic examination.

CONCLUSIONS

This pilot study shows that Euphorbia prostrata can be used as an effective and well-tolerated pharmaceutical agent in the treatment of early grades of hemorrhoids. Long-term follow-up and randomized control trials by comparing with other established formulations is necessary to justify reliance on this medication.

摘要

背景

在过去十年中，随着新的药物制剂的引入，痔疮的治疗方法发生了重大变化。地榆是一种用于 I 级和 II 级痔疮的新分子。地榆在痔疮中的有益作用有多种机制，这是由于其活性成分黄酮类、单宁和酚酸。本初步研究旨在评估这种分子在早期症状性痔疮中的疗效。

材料和方法

在本回顾性研究中，观察了地榆对地榆治疗痔疮患者的影响，随访时间为 12 周。共有 120 名患者参与了研究，其中男性 63 例，女性 57 例。I 级和 II 级患者每天早上空腹服用一片地榆片（Tab Sitcom，Panacea Biotec，印度），持续两周。在开始治疗后 2、4 和 12 周进行随访。本研究的主要终点是控制出血，次要终点是痔块消退、瘙痒和肛门不适缓解。

结果

99 例（82%）患者在两周结束时完全停止出血。6 例患者需要再治疗两周才能完全缓解，成功率为 87%。73%的患者瘙痒缓解，90%的患者肛门不适缓解。没有患者报告服用该药有任何不良反应。治疗 3 个月后的随访中，没有患者报告症状复发。然而，79 例患者中有 37 例（46%）在肛门镜检查时仍有残留痔疮。